Inogen, Inc.
INGN 4.5Price and target zones价格与目标区间
Near the buy zone接近买入区间
What the company does公司做什么
Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Read the full description查看完整介绍
Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It provides Inogen One and Inogen Rove, an ambulatory solution for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Rove 6 concentrator; Inogen Voxi 5, a stationary oxygen concentrator; Aurora for continuous positive airway pressure; CPAP masks; Simeox for airway clearance treatment; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Beverly, Massachusetts.
Products and services产品与服务 from the vendor summary — not yet written up来自供应商简介——尚未整理成文
- It provides Inogen One and Inogen Rove, an ambulatory solution for long-term oxygen therapy
- Rove 4, a portable oxygen concentrator
- Rove 6 concentrator
- Inogen Voxi 5, a stationary oxygen concentrator
- Aurora for continuous positive airway pressure
- CPAP masks
- Simeox for airway clearance treatment
- Related accessories It also rents its products directly to patients
Company facts公司资料
- Founded成立时间
- 2001
- Headquarters总部
- Beverly, Massachusetts
- Employees员工人数
- 753
- Industry行业
- Medical Devices
- Country国家
- United States
Investment thesis投资逻辑 from the watchlist来自关注列表
👀 Above entry $4.25-5.00 — ANALYZED 8/19, first file ever. WATCH, do not buy yet.
What's working
- Burn is collapsing: H1'26 FCF −$6.4M vs −$18.4M a year earlier, Q2 FCF positive, net loss halved YoY
- Gross margin 44.8%→45.5% against adverse mix (real cost work, partly lower warranty = a product-quality signal)
- Share count is FALLING 27.23M→26.73M — buybacks verified as genuine retirement via the APIC roll-forward (APIC −$4.0M while SBC added $3.7M) and running ahead of stock comp ($15M/yr vs $7.3M/yr); $22.5M of a $30M authorisation (~15% of shares at this price) still unused.
- Demand is intact — POC demand +12%, units up high-single-digits, international +14.8% for a 10th straight double-digit quarter; Philips Respironics exited POC in 2024
- Yuwell bought 9.9% at ~$10.36 (82% above spot) — note the vendor feeds report this deal backwards → [[pitfall-syndicated-research-inverts-strategic-investment-direction]]
Red flags
- Revenue has not grown in five years — FY26 guide $355-361M is still below FY2022's $377M; FY26 revenue guidance was cut on 8/07
- Opex ($192M/yr) exceeds gross profit ($158M/yr) by $34M — needs ~20% revenue growth just to cover today's cost base
- "Adjusted EBITDA positive" takes ~$15M of add-backs to turn −$11.0M GAAP EBITDA into +$4M, a 1.1% margin → [[pitfall-gate-cleared-by-adjective-not-arithmetic]]
- No breakeven date named when asked directly, in year five of operating losses
- Zero open-market insider buying; two officer sales — Yahoo's "insider purchases" here are $0.00 director grants → [[pitfall-yahoo-insider-purchases-counts-rsu-grants]]
- Three CEOs in five years
- Thin coverage (3 analysts, targets predate the cut) and thin tape (~250k sh/day). Metric that closes the gap: GAAP operating breakeven + continued share retirement — explicitly NOT a DTC recovery. FV $5.50-8.50. Entry $4.25-5.00 (at/below tangible book). Trim 14x EV/EBIT once operating income turns positive — a dollar trim is meaningless on negative earnings
Watch
- The weakest member of this sleeve on the sleeve's own test — and it is listed here with that stated, not hidden. The problem is not clearly fixable: Inogen's high-margin direct-to-consumer channel is structurally gone — HMEs now prescribe portable oxygen concentrators from day one — and the CEO declined to defend DTC when Needham called it "a melting ice cube," conceding the mix shift "has been happening faster than we anticipated." So the re-rate cannot come from repairing the channel. It has to come from the cost line and the share count, and that gap is real and narrow: EV $62M buys $158M of annual gross profit — 0.175x EV/Sales, 0.39x EV/gross profit, 0.87x book, 1.11x tangible book — on a company holding $89.7M net cash (59% of market cap) with zero funded debt (all $15.8M is finance leases) and ~10 years of runway. Solvency is not the question here; relevance is.
- Sleeve rule applies — exit when the gap closes.
- Cluster discipline: this is the seventh post-collapse, pre-inflection name in the book — see Concentration Map. Fund it as a swap, not an add.
Would upgrade on
- Upgrade: two quarters of >5% revenue growth or DTC stabilising a committed breakeven date any open-market insider purchase buyback accelerating toward the full $30M.
🆕 2026年8月19日分析——史上第一份文件。 观望（WATCH），现在不要买入。 ** ⚠️ 这是「重估」这个筐里最弱的一个，而且这一点是写明的、不是藏起来的。 ** 它的问题并不明确可修复：Inogen 高毛利的直销（DTC）渠道在结构上已经消失——家用医疗设备商（HME）现在从第一天起就直接开便携制氧机；当 Needham 把 DTC 形容为「正在融化的冰块」时，CEO 没有为它辩护，并承认这一渠道结构转变「比我们预期的来得更快」。 所以重估不可能来自修复渠道。 ** 它只能来自成本线和股本，而这个缺口是真实且明确的：$62M 的企业价值买到的是每年 $158M 的毛利——0.175 倍 EV/销售额、0.39 倍 EV/毛利、0.87 倍市净率、1.11 倍有形市净率——公司手握 $89.7M 净现金（占市值 59%），没有任何有息负债（$15.8M 全部是融资租赁），现金可以撑约 10 年。 这里的问题不是能不能活下来，而是还重不重要。 ** ✅ 现金消耗正在快速收窄： 2026 上半年自由现金流 −$6.4M，去年同期为 −$18.4M，第二季度自由现金流转正，净亏损同比腰斩。 ✅ 在产品结构恶化的情况下毛利率仍从 44.8% 升到 45.5%（真实的成本改善，其中一部分来自保修费用下降＝产品质量的信号）。 ✅ 股数在下降，27.23M→26.73M——通过股本溢价（APIC）的滚动核对确认这是真实注销（APIC 减少 $4.0M，而股权激励增加 $3.7M），并且回购金额高于股权激励（每年 $15M 对 $7.3M）；$30M 授权中仍有 $22.5M 未动用（按现价约合 15% 的股本）。 ** ✅ 需求本身没有问题——便携制氧机需求 +12%，出货量高个位数增长，国际业务 +14.8%，连续第 10 个季度双位数增长；飞利浦伟康已于 2024 年退出该市场。 ✅ 鱼跃医疗以 约 $10.36（高出现价 82%）买入 9.9% 股份——注意各家数据商把这笔交易的方向报反了 → [[pitfall-syndicated-research-inverts-strategic-investment-direction]]。 🚩 但收入已经五年没有增长——2026 财年指引 $355-361M 仍低于 2022 财年的 $377M；而且 8 月 7 日刚下调了 2026 财年收入指引。 🚩 运营费用（每年 $192M）比毛利（每年 $158M）高出 $34M——光是要覆盖今天的成本基础，收入就得再涨约 20%。 🚩 所谓「调整后 EBITDA 转正」需要约 $15M 的加回项，才能把 −$11.0M 的 GAAP EBITDA 变成 +$4M，对应利润率仅 1.1% → [[pitfall-gate-cleared-by-adjective-not-arithmetic]]。 🚩 在连续第五年经营亏损的情况下，被直接问及时管理层没有给出盈亏平衡的时间表。 🚩 没有任何公开市场的内部人买入，只有两笔高管卖出——雅虎在这里显示的「内部人买入」其实是 $0.00 的董事股权授予 → [[pitfall-yahoo-insider-purchases-counts-rsu-grants]]。 🚩 五年换了三任 CEO。 🚩 覆盖极少（3 位分析师，且目标价早于本次指引下调）、成交极薄（每日约 25 万股）。 能够收敛估值缺口的指标是：GAAP 经营层面转为盈亏平衡＋股数持续减少——明确不是 DTC 的复苏。 ** 合理价值 $5.50-8.50。 买入区间 $4.25-5.00（等于或低于有形账面价值）。 在经营利润转正之后，按 14 倍 EV/EBIT 减仓——在利润为负时设一个固定美元减仓价没有意义。 ⚠️ 适用本筐的规则——缺口收敛即退出。 * ⚠️ *组合纪律：这是本清单中第七个「崩塌之后、拐点未至」的名字——见集中度地图。 **
Historical results历史业绩 past fiscal years — these values do not change过去财年——这些数值不会变动
Profit margins利润率 the share of revenue that stays as profit营收中留存为利润的比例
of every $1 of revenue每 $1 营收中的占比
- Return on equity净资产收益率
- -13%
- Revenue growth营收增长
- +3%
Competitive advantages竞争优势 from the thesis and the reports来自投资逻辑和报告
- Phase 2 — Moat & competitive position The honest verdict: the moat is gone, and a smaller one is being rebuilt Inogen's moat was channel ownership , not technology.
- That moat has been taken apart by HME behaviour, and no patent protects it.
- The barriers that remain are FDA clearance, clinical evidence, brand, service network, and HME relationships — real frictions, but months-to-years frictions, not decades.
- The moat was channel ownership, not technology.
- Phase 6 — Debate round Tension: Fundamentals says "improving"; Moat says "structurally impaired." Both are right.
Related companies相关公司 🟠 Post-collapse, pre-inflection (new 8/20)
Not a sector — a thesis shape. Every one is a former high-flier bought after a collapse, each needing a revenue inflection that has not arrived.
The sleeve is full before a new name is judged on merit. New entries here are swaps, not adds — fund from an existing member.